Stephen R. Saklad, PharmD, BCPP

A consensus panel reviews the pharmacokinetic advantages and clinical utility of long-acting injectable aripiprazole monohydrate to optimize treatment for schizophrenia and bipolar I disorder.

Treatment with a combination of olanzapine and samidorphan was associated with less weight gain and reduced risk of reaching ≥7% or ≥10% gain in body weight versus olanzapine over...

In separate studies of the two initiation methods, the numbers of people who had side effects were similar, and most side effects were mild.